Amneal Focuses On Complex Generics As Revenues See Double-Digit Growth

Company Also Plans To File 30 ANDAs This Year

 
• By Akriti Seth

After launching several high-value complex generic products in the last six months, Amneal aims to launch eight more complex generics by August 2021 to add “tremendous value” to its generics business. 

Rocket
Amneal’s generics business sees double-digit growth, as the company prepares for more complex generic product launches • Source: Shutterstock

Amneal Pharmaceuticals has reported a 17% jump in its generics revenue to $342m in the third quarter of 2020, compared to the prior-year period. Commenting on the growth of the generics division, Chirag Patel, co-CEO, president and director of Amneal, said “the double-digit net revenue growth reflects the successful launch of eight of the 15 complex new products we target launching by August 2021.”

Chintu Patel, co-CEO and director of Amneal commented that “our generics business continues to improve with strong sales and increasing margins

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business